Oslo, Norway, 7 May 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its first quarter 2013 results on Wednesday, 15 May 2013. A presentation by Algeta's senior management team to investors, analysts and the press will take place in Oslo at 10:00 CET.
The presentation will also be webcast live and can be accessed through www.algeta.com (http://www.algeta.com/webcast) where questions can also be submitted during the presentation.
The presentation will take place at 10:00 CET at:
Shippingklubben
Haakon VIIs gate 1
0161 Oslo
Norway.
Algeta's senior management will also host an international conference call at 14:30 CET/08:30 Eastern Time (US) (details below).
To participate in the conference call, please dial the appropriate number below five minutes prior to the call:
US: +1 877 423 0830
UK: +44 20 7153 9154
Norway: +47 21 06 61 13
Sweden: +46 8-506 443 86
Denmark: +45 32 71 42 62
Switzerland: +41 44 580 65 22
Participant pin code: 281404#
To access the replay, please dial:
US: +1 877 679 2989
UK: +44 20 3364 5196
Norway: +47 23 50 02 03
Sweden: +46 8-505 564 73
Conference reference: 346423#
A replay version of the conference call will also be available at www.algeta.com (http://www.algeta.com/).
The results report and the presentation will be available at www.algeta.com (http://www.algeta.com/) in the Investors section from 07:00 CET.
###
For further information, please contact:
| Mike Booth / Renate Birkeli | +47 23 00 67 32 |
| Communications & Corporate Affairs | ir@algeta.com (mailto:ir@algeta.com) |
| Media enquiries: | |
| Mark Swallow | +44 207 638 9571 |
| Citigate Dewe Rogerson | mark.swallow@citigatedr.co.uk (mailto:mark.swallow@citigatedr.co.uk) |
| Knut Ekern | +47 22 04 82 00 |
| Gambit Hill & Knowlton | knut.ekern@hkstrategies.com (mailto:knut.ekern@hkstrategies.com) |
| Kari Watson | +1 781 235 3060 |
| MacDougall Biomedical Communications | kwatson@macbiocom.com (mailto:kwatson@macbiocom.com) |
| US investor enquiries: | |
| Tricia Swanson | +1 646 378 2953 |
| The Trout Group | tswanson@troutgroup.com (mailto:tswanson@troutgroup.com) |
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com (http://www.algeta.com/).
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
